|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||63.5700 - 64.1000|
|52 Week Range||46.3100 - 64.6900|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
The healthcare sector is the second-best performer in the S&P 500 this year behind technology. Traditional, diversified healthcare exchange traded funds are delivering for investors. Just look at the Health ...
Goldman Sachs' Patrick Donnelly and Charles Steinman assumed coverage of the life science tools and diagnostics sector with a Neutral rating today: While the believe that strong end markets provide one of the best, sustainable growth profiles in healthcare, that fact is already reflected in valuations. Donnelly and Steinman write that the end markets for this sector, including biopharma, academic/government, industrial/applied, and clinical, will stay healthy, which translates into organic growth of 4% to 5%, for the tools and diagnostics industries--although that is down slightly from recent 5% to 6% growth. The main driver of this is their anlaysis that shows biopharma market will decelerate to mid-single digit growth, on slowing R&D spending, along with risk from M&A and drug pricing legislation.
Among cancers, lung cancer is the deadliest worldwide, largely because of late diagnoses. Morgan Stanley’s David Lewis and his team write that new tools can disrupt the $6 billion lung biopsy market with better precision and diagnostic accuracy—and that a new system developed via a joint venture between Intuitive Surgical (ISRG) and Fosun International (656.Hong Kong), might be just that tool. Lewis writes that currently, lung biopsy methods have low yields and carry risks, which delays diagnosis and treatment, but that the FC system—a robotic controlled biopsy system using 3D imaging technology to target potential tumors—is more accurate and comes with fewer side effects, which could lower lung cancer mortality.
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
Medical related ETFs have racked up healthy gains this year amid the ongoing quest for longer and healthier lives.
As has been widely documented, the healthcare sector, the S&P 500's third-largest sector weight, is struggling this year. The Health Care SPDR (ETF) (NYSE: XLV ), the largest healthcare exchange-traded ...
Novartis got government approval for a new cancer therapy. The treatment will cost a staggering $475,000, and it will help children and young adults with a certain type of Leukemia. Yahoo Finance's Seana Smith, Nicole Smith and Rick Newman react to what Wall Street is saying about the drug.